longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Seres Therap

MCRB

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -2.12, within the reasonable range, cheaper than 50.58% of the time in the past 5 years, and the industry ranks 255/601, the industry Median -2.49.

-2.12xP/E
$4.73Stock price
$-2.24Earnings per share
-2.12xP/E
Stock price$4.73Earnings per share$-2.24

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-2.06x
Typical range
-4.86x–1.30x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-56.03x148.77%$181.54B
CSLLYUSCSL Limited
-22.82x--$58.85B
MRNAUSModerna
-18.59x15.47%$58.56B
NTRAUSNatera
-256.14x10.38%$49.27B
RVMDUSRevolution Medicines
-24.86x64.29%$43.96B
ROIVUSRoivant Sciences
-111.28x148.13%$29.63B
INSMUSInsmed
-31.26x74.48%$27.36B
BNTXUSBioNTech SE
-12.69x19.70%$24.83B
SMMTUSSummit Therapeutics
-17.16x18.42%$14.69B
BBIOUSBridgebio Pharma
-20.45x28.57%$14.15B
MDGLUSMadrigal Pharma
-38.38x50.86%$12.48B
ARWRUSArrowHead Pharma
-35.61x36,308.30%$11.39B
CYTKUSCytokinetics
-11.27x6.37%$10.07B
ABVXUSAbivax SA
-25.51x32.59%$9.90B
KYMRUSKymera Therapeutics
-31.81x4.94%$9.53B
PRAXUSPraxis Precision Medicines
-27.21x3.05%$9.23B
TWSTUSTwist Bioscience
-64.89x24.70%$8.87B
IBRXUSImmunityBio
-8.94x152.63%$8.87B
PCVXUSVaxcyte
-8.32x48.80%$8.86B
IONSUSIonis Pharma
-15.13x50.13%$8.55B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.